Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.

Trial Profile

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications B cell lymphoma; B-cell leukaemia; Graft-versus-host disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics Switzerland
  • Most Recent Events

    • 06 Mar 2018 Planned End Date changed from 1 May 2020 to 2 Jul 2027.
    • 06 Mar 2018 Planned primary completion date changed from 1 May 2020 to 2 Jul 2027.
    • 29 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top